Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 200 Total
AIP - Arteris Inc - Stock Price Chart
TickerAIP [NASD]
CompanyArteris Inc
CountryUSA
IndustrySemiconductors
Market Cap268.59MEPS (ttm)-1.03
P/E-EPS this Y12.40%
Forward P/E-EPS next Y52.75%
PEG-EPS past 5Y-
P/S5.00EPS next 5Y-
P/B17.39EPS Q/Q-33.29%
Dividend-Sales Q/Q11.61%
Insider Own40.41%Inst Own30.82%
Insider Trans-1.40%Inst Trans14.28%
Short Float0.82%EarningsMay 02/a
Analyst Recom1.00Target Price12.75
Avg Volume149.65K52W Range3.72 - 8.08
Today 08:17AM Q1 2024 Arteris Inc Earnings Call (Thomson Reuters StreetEvents) +18.04%
04:05AM Arteris Inc (AIP) Q1 2024 Earnings Call Transcript Highlights: Navigating Through Challenges ... (GuruFocus.com)
May-02-24 09:56PM AIP Stock Earnings: Arteris Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -5.12%
06:07PM Arteris Inc (AIP) Q1 2024 Earnings: Misses EPS Estimates Amidst Strategic Expansions (GuruFocus.com)
04:05PM Arteris Announces Financial Results for the First Quarter 2024 and Second Quarter and Full Year 2024 Guidance (GlobeNewswire)
Apr-23-24 08:00AM Arteris to Announce Financial Results for the First Quarter 2024 on Thursday, May 2, 2024 (GlobeNewswire)
Apr-09-24 08:45AM Rebellions Selects Arteris for Its Next-Generation Neural Processing Unit Aimed at Generative AI (GlobeNewswire) +6.65%
Mar-14-24 11:50AM Arteris (AIP) Expands Portfolio With Latest ARM-based Solutions (Zacks)
Mar-13-24 09:05AM Arteris Expands Automotive Solutions for Armv9 Architecture CPUs (GlobeNewswire)
09:00AM Arteris Expands Ncore Cache Coherent Interconnect IP To Accelerate Leading-Edge Electronics Designs (GlobeNewswire)
AGBA - AGBA Group Holding Limited - Stock Price Chart
TickerAGBA [NASD]
CompanyAGBA Group Holding Limited
CountryHong Kong
IndustryCapital Markets
Market Cap243.26MEPS (ttm)-0.75
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-332.18%
P/S4.49EPS next 5Y-
P/B27.71EPS Q/Q-322.41%
Dividend-Sales Q/Q-
Insider Own0.00%Inst Own0.04%
Insider Trans-Inst Trans0.47%
Short Float0.03%EarningsNov 14/b
Analyst Recom-Target Price-
Avg Volume11.44M52W Range0.32 - 4.29
Apr-30-24 12:45PM AGBA Stock Pops 35% on Triller Merger Update (InvestorPlace) +20.43%
09:00AM Building a Digital Economy Titan: AGBA and Triller Combine in $4 Billion Merger (GlobeNewswire)
Apr-25-24 04:15PM AGBA Stands Firm: The AGBA-Triller Merger is Value-Enhancing to All Stakeholders (GlobeNewswire) -8.57%
Apr-22-24 10:57AM BestGrowthStocks.com Unveils In-Depth Review of Triller Merger with AGBA Group Holding Limited (News Direct) +100.00%
Apr-19-24 08:32AM AGBA/TRILLER $4 billion MERGER: ELEVATING SHAREHOLDER VALUE TO NEW HEIGHTS - IMMEDIATELY AND FOR THE LONG TERM (GlobeNewswire) +21.36%
Apr-18-24 08:00AM AGBA and Triller Merge to Create a $4 Billion Powerhouse, Unleashing a Game-Changing Power in Digital Content and Financial Services (GlobeNewswire) +157.50%
Mar-28-24 04:10PM AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro Environment. (GlobeNewswire)
Mar-06-24 07:00AM Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire)
Mar-05-24 07:00AM Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
05:00AM Asian Financial Services Stocks Could Soar As Economic Tailwinds Intensify (News Direct)
DNTH - Dianthus Therapeutics Inc - Stock Price Chart
TickerDNTH [NASD]
CompanyDianthus Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap766.92MEPS (ttm)-13.05
P/E-EPS this Y77.08%
Forward P/E-EPS next Y-18.85%
PEG-EPS past 5Y29.95%
P/S555.74EPS next 5Y-
P/B2.29EPS Q/Q86.61%
Dividend-Sales Q/Q-
Insider Own26.58%Inst Own42.66%
Insider Trans0.00%Inst Trans5.07%
Short Float8.86%EarningsMar 21/a
Analyst Recom1.17Target Price50.17
Avg Volume171.39K52W Range6.58 - 33.77
Apr-11-24 07:30AM Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 10:54PM DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-22-24 07:30AM Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
SNSE - Sensei Biotherapeutics Inc - Stock Price Chart
TickerSNSE [NASD]
CompanySensei Biotherapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap43.12MEPS (ttm)-1.21
P/E-EPS this Y19.37%
Forward P/E-EPS next Y-5.23%
PEG-EPS past 5Y-16.26%
P/S-EPS next 5Y-
P/B0.66EPS Q/Q25.56%
Dividend-Sales Q/Q-
Insider Own35.02%Inst Own11.02%
Insider Trans0.00%Inst Trans-0.13%
Short Float0.50%EarningsFeb 28/b
Analyst Recom1.00Target Price4.67
Avg Volume150.96K52W Range0.51 - 1.92
Apr-24-24 04:05PM Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-09-24 07:30AM Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference (GlobeNewswire) +6.28%
Apr-04-24 04:05PM Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment (GlobeNewswire)
Mar-22-24 07:30AM Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium (GlobeNewswire) +11.43%
Mar-06-24 07:30AM Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Feb-28-24 07:30AM Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +9.09%
Feb-07-24 07:30AM Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +6.12%
Jan-04-24 07:30AM Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-07-23 08:09AM Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results (GuruFocus.com) -7.15%
07:30AM Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
KOP - Koppers Holdings Inc - Stock Price Chart
TickerKOP [NYSE, RUT]
CompanyKoppers Holdings Inc
CountryUSA
IndustrySpecialty Chemicals
Market Cap998.17MEPS (ttm)4.15
P/E11.36EPS this Y7.11%
Forward P/E8.95EPS next Y12.78%
PEG0.63EPS past 5Y30.43%
P/S0.46EPS next 5Y18.00%
P/B1.97EPS Q/Q-9.18%
Dividend0.53%Sales Q/Q6.34%
Insider Own4.37%Inst Own93.03%
Insider Trans-22.44%Inst Trans0.37%
Short Float1.63%EarningsMay 03/b
Analyst Recom1.00Target Price65.50
Avg Volume121.44K52W Range28.45 - 58.23
Today 09:56AM Koppers Shares Fall After Lower Q1 Adjusted Earnings, Net Sales; 2024 Adjusted EPS Outlook Trimmed (MT Newswires) -10.89%
09:36AM Koppers Reports First Quarter 2024 Results; Provides Updated 2024 Outlook (PR Newswire)
09:36AM /C O R R E C T I O N -- KOPPERS HOLDINGS INC./ (PR Newswire)
08:02AM Koppers: Q1 Earnings Snapshot (Associated Press Finance)
May-02-24 10:51AM Koppers Holdings Inc. Declares Quarterly Cash Dividend (PR Newswire)
Apr-26-24 10:00AM Koppers (KOP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-19-24 07:55AM Koppers Holdings Inc. Schedules First Quarter 2024 Conference Call (PR Newswire)
Apr-16-24 06:52AM Koppers (KOP) Concludes Repricing & Upsizing of Term Loan B (Zacks)
Apr-15-24 07:55AM Koppers Successfully Reprices and Upsizes Term Loan B (PR Newswire)
Apr-04-24 01:18PM Koppers (KOP) Wraps Up Acquisition of Brown Wood Preserving (Zacks)
UK - Ucommune International Ltd - Stock Price Chart
TickerUK [NASD]
CompanyUcommune International Ltd
CountryChina
IndustryReal Estate Services
Market Cap1.08MEPS (ttm)-5.37
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-250.49%
P/S0.02EPS next 5Y-
P/B0.15EPS Q/Q-719.46%
Dividend-Sales Q/Q12.70%
Insider Own14.07%Inst Own0.13%
Insider Trans0.00%Inst Trans-0.63%
Short Float6.89%Earnings-
Analyst Recom-Target Price-
Avg Volume183.47K52W Range1.88 - 12.60
Dec-15-23 06:30AM Ucommune Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -5.14%
Dec-14-23 06:30AM Joining Hands Towards a Shared Future----Signing Ceremony of Strategic Cooperation Between Ucommune and New World Development (Wuhan) Limited & Forum on Optimizing Building Economy and Collaborating for Breakthrough Development Successfully Held (PR Newswire)
Nov-29-23 09:00AM Ucommune Announces Extraordinary General Meeting Results and Share Consolidation (PR Newswire) +45.63%
Oct-24-23 07:30AM Ucommune and Plateno Hotel: A Powerhouse Partnership Set to Transform the Hotel and Co-working Space (PR Newswire) +7.92%
Oct-13-23 05:00PM Ucommune Announces Extraordinary General Meeting (PR Newswire) +8.10%
Jul-24-23 04:00PM Ucommune Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire)
Jan-03-23 06:30AM Ucommune Launches "Up to U" Digital Apartment Management Platform (PR Newswire)
Oct-26-22 07:00AM Ucommune Delivers Customized Office Space with All-In-One Solution (PR Newswire) -13.96%
Oct-11-22 07:00AM Ucommune and Zhuhai Gree Real Estate Co., Ltd. Enter into an Agreement to Create a Benchmark Coworking Space in Greater Bay Area, China (PR Newswire) +5.95%
Oct-04-22 07:00AM Ucommune Completes Digital Operation Management Across All Its Managed Locations Using SaaS (PR Newswire)
BNTC - Benitec Biopharma Inc - Stock Price Chart
TickerBNTC [NASD]
CompanyBenitec Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap24.22MEPS (ttm)-10.90
P/E-EPS this Y82.79%
Forward P/E-EPS next Y27.98%
PEG-EPS past 5Y66.41%
P/S403.61EPS next 5Y-
P/B1.57EPS Q/Q20.94%
Dividend-Sales Q/Q-100.00%
Insider Own6.81%Inst Own103.68%
Insider Trans0.00%Inst Trans-
Short Float0.51%EarningsFeb 13/b
Analyst Recom1.00Target Price16.00
Avg Volume86.09K52W Range1.86 - 9.46
May-01-24 08:00AM Benitec Biopharma to Participate in the Citizens JMP Life Science Conference (GlobeNewswire) -6.51%
Apr-18-24 07:30AM Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study (GlobeNewswire) +42.08%
07:00AM Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million (GlobeNewswire)
Apr-09-24 08:00AM Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024 (GlobeNewswire)
Mar-24-24 07:55AM 11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-13-24 08:00AM Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-30-23 07:00AM Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (GlobeNewswire)
Nov-17-23 08:00AM Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 08:00AM Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Sep-21-23 08:00AM Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update (GlobeNewswire)
CTMX - CytomX Therapeutics Inc - Stock Price Chart
TickerCTMX [NASD]
CompanyCytomX Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap323.02MEPS (ttm)-0.02
P/E-EPS this Y-3686.00%
Forward P/E-EPS next Y-11.90%
PEG-EPS past 5Y67.21%
P/S3.19EPS next 5Y-0.90%
P/B-EPS Q/Q109.36%
Dividend-Sales Q/Q32.22%
Insider Own1.84%Inst Own48.12%
Insider Trans-5.72%Inst Trans-20.06%
Short Float5.41%EarningsMar 11/a
Analyst Recom2.86Target Price2.85
Avg Volume4.52M52W Range1.04 - 5.85
May-02-24 08:08AM CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-01-24 12:11PM Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally (InvestorPlace) +214.72%
11:43AM Why Is CytomX (CTMX) Stock Up 180% Today? (InvestorPlace)
08:00AM CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
Apr-03-24 08:00AM CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-21-24 08:00AM CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors (GlobeNewswire)
Mar-18-24 08:00AM CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-12-24 09:12AM Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today? (InvestorPlace) -14.34%
CDTX - Cidara Therapeutics Inc - Stock Price Chart
TickerCDTX [NASD]
CompanyCidara Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap59.28MEPS (ttm)-5.16
P/E-EPS this Y-147.63%
Forward P/E-EPS next Y57.52%
PEG-EPS past 5Y37.54%
P/S0.93EPS next 5Y-
P/B-EPS Q/Q66.68%
Dividend-Sales Q/Q72.06%
Insider Own9.96%Inst Own29.25%
Insider Trans-15.15%Inst Trans-
Short Float0.20%EarningsApr 22/a
Analyst Recom1.00Target Price72.50
Avg Volume60.69K52W Range10.00 - 29.60
Apr-26-24 08:00AM Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 (GlobeNewswire)
Apr-25-24 12:22PM Cidara buys back rights to flu therapy from J&J for $85m (Pharmaceutical Technology) +5.78%
07:52AM Top Premarket Gainers (MT Newswires)
Apr-24-24 04:05PM Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million (GlobeNewswire) +19.90%
04:01PM Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline (GlobeNewswire)
Apr-23-24 05:11AM Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket (MT Newswires)
Apr-22-24 09:52PM CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -24.54%
05:10PM Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
05:06PM Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice (GlobeNewswire)
08:49AM Cidara Therapeutics Announces Reverse Stock Split (GlobeNewswire)
LYEL - Lyell Immunopharma Inc - Stock Price Chart
TickerLYEL [NASD, RUT]
CompanyLyell Immunopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap609.31MEPS (ttm)-0.94
P/E-EPS this Y6.33%
Forward P/E-EPS next Y-5.17%
PEG-EPS past 5Y-15.28%
P/S4686.97EPS next 5Y-7.90%
P/B0.93EPS Q/Q-522.32%
Dividend-Sales Q/Q-99.97%
Insider Own53.66%Inst Own27.73%
Insider Trans0.00%Inst Trans4.25%
Short Float15.43%EarningsFeb 29/b
Analyst Recom1.67Target Price7.50
Avg Volume901.40K52W Range1.32 - 3.97
Mar-19-24 10:00AM CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
Mar-07-24 12:00PM Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know (Zacks)
Mar-05-24 04:30PM Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting (GlobeNewswire)
Feb-28-24 04:44PM Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights (GuruFocus.com)
04:05PM Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-26-24 04:05PM Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +9.62%
Jan-03-24 04:05PM Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.69%
Nov-09-23 04:05PM Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma (GlobeNewswire) -6.81%
Nov-07-23 04:33PM Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
1234567891011⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.